text
stringlengths
1
5.46k
Investors:
Laurence Watts, Gilmartin Group, LLC.:
619-916-7620
laurence@gilmartinir.com 
AbbVie
Media:
Adelle Infante
847-938-8745
adelle.infante@abbvie.com 
Investors:
Liz Shea
847-935-2211
liz.shea@abbvie.com 
Source: Alpine Immune Sciences Inc.; AbbVie Inc.
Schedule 10.2
Licensor Disclosure Schedule
Section 10.2.2 The Identified Patent described in Schedule 6.6.3(c) (Special Offset).
Schedule 10.2.1
Existing Licensor Product Patents
AIS Family No. 03 Attorney Reference No. 76161.x0003.xx ICOS LIGAND VARIANT IMMUNOMODULATORY PROTEINS AND USES THEREOF
Country Atty. Ref. Application No. (Country Filing Date) Publication No. (Publication Date) Status and Comments
US 30003.00 62/323,608 (4/15/2016) None Expired
US 30003.01 62/394,745 (9/14/2016) None Expired
US 30003.02 62/410,842 (10/20/2016) None Expired
US 30003.03 62/472,568 (3/16/2017) None Expired
US 30003.04 62/475,162 (3/22/2017) None Expired
PCT 20003.40 PCT/US2017/027811 (4/14/2017) WO 2017/181148 (10/19/2017) Expired; Nat'l phase filed
AU 20003.41 2017250358 (9/26/2018) AU-A-2017250358 (10/18/2018) Pending
BR 20003.42 BR 11 2018 070934 4 (10/10/2018) BR1120180709344 (2/26/2019) Pending
CA 20003.43 3,019,199 (9/26/2018) CA 3019199 (10/04/2018) Pending
CN 20003.44 201780036984.0 (12/13/2018) CN 110088126 (08/02/2019) Pending
EA 20003.45 201892336 (11/14/2018) EA 201892336 (06/28/2019) Pending
EP 20003.46 17733114.7 (9/28/2018) EP 3442999 (02/20/2019) Pending
IL 20003.47 262365 (10/14/2018) IL 262365 (11/29/2018) Pending
IN 20003.48 201817041129 (10/31/2018) IN 201817041129 (03/01/2019) Pending
JP 20003.49 2018-554101 (12/10/2018) JP 2019514361 (06/06/2019) Pending
KR 20003.50 10-2018-7033049 (11/14/2018) KR 20190005879 (01/16/2019) Pending
MX 20003.51 MX/a/2018/012472 (10/11/2018) MX/a/2018/012472 (09/06/2019) Pending
NZ 20003.52 746741 (9/26/2018) NZ 746741 A1 (09/28/2019) Pending
SG 20003.53 11201808457P (9/27/2018) SG 11201808457P (10/30/2018) Pending
HK (EP) 20003.54 19121707.4 (4/1/2019) HK 1261801 (1/3/2020) Pending
HK (CN) 20003.55 19128847.1 (8/28/2019) Not yet published Pending
US 20003.00 15/488409 (04/14/2017) US 2017/0320959 (11/9/2017) Pending
AIS Family No. 07
MULTI-DOMAIN IMMUNOMODULATORY PROTEINS AND METHODS OF USE THEREOF Country Atty. Ref. Application No. (Country Filing Date) Publication No. (Publication Date) Status and Comments
US 30007.00 62/613,378 (01/03/2018) None Expired
US 30007.01 62/733,622 (09/19/2018) None Expired
PCT 20007.40 PCT/US2019/012222 (01/03/2019) WO 2019/136179 (07/11/2019) Pending
AIS Family No. 12 Attorney Reference No. 76161.x0022.xx VARIANT ICOS LIGAND IMMUNOMODULATORY PROTEINS AND RELATED COMPOSITIONS AND METHODS
Country Atty. Ref. Application No. (Country Filing Date) Publication No. (Publication Date) Status and Comments
US 30022.00 62/574,161 (10/18/2017) None Expired
AR 20022.41 20180103041 (10/18/2018) None Pending
TW 20022.42 107136610 (10/17/2018) 201925223 (07/01/2019) Pending
PCT 20022.40 PCT/US2018/056381 (10/17/2018) WO 2019/079520 (04/25/2019) Expired; Nat'l phase filed by 18 April 2020
AU 20022.43 2018351000 (4/9/2020) AU-A1-2018351000 (04/30/2020) Pending
BR 20022.44 BR 11 2020 007542 6 (4/16/2020) Not yet published Pending
CA 20022.45 3,078,517 (4/3/2020) CA 3078517 A1 (04/25/2019) Pending
CN 20022.46 Not yet available Not yet published Pending
EA 20022.47 202090974 (05/15/2020) Not yet published Pending
EP 20022.48 18803814.5 (4/1/2020) Not yet published Pending
IL 20022.49 273726 (3/31/2020) Not yet published Pending
IN 20022.50 20201701941 (05/07/2020) Not yet published Pending
JP 20022.51 2020-521877(4/17/2020) Not yet published Pending
KR 20022.52 Not yet available Not yet published Pending
MX 20022.53 MX/a/2020/004540 (4/30/2020) Not yet published Pending
NZ 20022.54 763426 (4/9/2020) Not yet published Pending
SG 20022.55 11202003078V (4/2/2020) Not yet published Pending
UAE 20022.56 P6000549/20 (4/15/2020) Not yet published Pending
BH 20022.57 20200069 (4/16/2020) Not yet published Pending
MY 20022.60 PI2020001960 (4/18/2020) Not yet published Pending
PH 20022.62 Not yet available Not yet published Pending
QA 20022.63 QA/202004/00202 (4/15/2020) Not yet published Pending
SA 20022.64 520411779 (4/16/2020) Not yet published Pending
UA 20022.66 a202002918 (5/15/2020) Not yet published Pending
ZA 20022.67 2020/02826 (5/15/2020) Not yet published Pending
US 20022.00 16/757,344 (4/17/2020) Not yet published Pending
AIS Family No. 20 Attorney Reference No. 76161.x0032.xx METHODS AND USES OF VARIANT ICOS LIGAND (ICOSL) FUSION PROTEINS
Country Atty. Ref. Application No. (Country Filing Date) Publication No. (Publication Date) Status and Comments
US 30032.00 62/635488 (04/17/2019) None Expired
US 30032.01 62/855830 (5/31/2019) None Pending
US 30032.02 62/931212 (11/5/2019) None Pending
US 30032.03 62/945071 (12/06/2019) None Pending
US 30032.04 62/962,832 (01/17/2020) None Pending
US 30032.05 62/987,854 (03/10/2020) None Pending
PCT 20032.40 PCT/US2020/028601 (4/16/2020) Not yet published Pending
Schedule 13.1
Approved Third Party Providers
Current Potential for future Clinical - HV Nucleus Network/CPR, Covance, or QPS Clinical - SLE N/A IQVIA, PRA or Parexel
Nonclinical CRL
Clinical BioA PPD, 360Biolabs and/or PRA, Northwest Pk Solutions
Toxicology
Toxicology Alta Biosciences
Regulatory
Reg Ops Pharmaceutical eConsulting, Accenture, Acuta, BDO
EU Reg RegIntel, Voisin, Jenkins & Jenkins, Ltd.
Other Reg ICON (Mapi Group), Parexel
INN Brand Institute
Biomarkers
Flow In-house, 360biolabs Q2
CMC